774 related articles for article (PubMed ID: 23040208)
21. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
[TBL] [Abstract][Full Text] [Related]
22. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
24. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
25. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men.
Leder BZ; Smith MR; Fallon MA; Lee ML; Finkelstein JS
J Clin Endocrinol Metab; 2001 Feb; 86(2):511-6. PubMed ID: 11158001
[TBL] [Abstract][Full Text] [Related]
26. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
[TBL] [Abstract][Full Text] [Related]
29. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
30. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
31. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
[TBL] [Abstract][Full Text] [Related]
32. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Miller PD; Epstein S; Sedarati F; Reginster JY
Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
Yan Y; Wang W; Zhu H; Li M; Liu J; Luo B; Xie H; Zhang G; Li F
J Bone Miner Metab; 2009; 27(4):471-8. PubMed ID: 19343272
[TBL] [Abstract][Full Text] [Related]
34. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
[TBL] [Abstract][Full Text] [Related]
35. Prevention of bone loss after withdrawal of tamoxifen.
Cohen A; Fleischer JB; Johnson MK; Brown IN; Joe AK; Hershman DL; McMahon DJ; Silverberg SJ
Endocr Pract; 2008 Mar; 14(2):162-7. PubMed ID: 18308653
[TBL] [Abstract][Full Text] [Related]
36. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
37. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
38. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
[TBL] [Abstract][Full Text] [Related]
39. Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study.
Rodrigues P; Meler A; Hering F
Urol Int; 2010; 85(2):180-5. PubMed ID: 20628233
[TBL] [Abstract][Full Text] [Related]
40. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
